Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LXEO NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXEOLexeo Therapeutics$5.11-2.3%$5.88$2.51▼$10.99$401.25M1.52752,406 shs461,190 shsTNXPTonix Pharmaceuticals$12.77-8.8%$13.75$11.60▼$69.97$203.57M1.68399,540 shs617,970 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXEOLexeo Therapeutics0.00%+0.39%-14.98%-18.76%+66.99%TNXPTonix Pharmaceuticals0.00%-18.87%+2.24%-9.05%-54.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXEOLexeo Therapeutics$5.11-2.3%$5.88$2.51▼$10.99$401.25M1.52752,406 shs461,190 shsTNXPTonix Pharmaceuticals$12.77-8.8%$13.75$11.60▼$69.97$203.57M1.68399,540 shs617,970 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXEOLexeo Therapeutics0.00%+0.39%-14.98%-18.76%+66.99%TNXPTonix Pharmaceuticals0.00%-18.87%+2.24%-9.05%-54.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLXEOLexeo Therapeutics 2.89Moderate Buy$18.88269.37% UpsideTNXPTonix Pharmaceuticals 2.67Moderate Buy$22.0072.28% UpsideCurrent Analyst Ratings BreakdownLatest TNXP and LXEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026LXEOLexeo Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.005/5/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/4/2026TNXPTonix Pharmaceuticals TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.005/1/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026TNXPTonix Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLXEOLexeo TherapeuticsN/AN/AN/AN/A$2.95 per shareN/ATNXPTonix Pharmaceuticals$13.11M15.53N/AN/A$14.25 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%N/ATNXPTonix Pharmaceuticals-$124.02M-$14.36N/AN/AN/A-839.52%-67.65%-60.47%8/10/2026 (Estimated)Latest TNXP and LXEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A5/11/2026Q1 2026TNXPTonix Pharmaceuticals-$2.54-$2.93-$0.39-$2.93$6.13 million$6.88 million3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/A3/12/2026Q4 2025TNXPTonix Pharmaceuticals-$3.16-$3.98-$0.82-$3.98$2.97 million$5.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLXEOLexeo TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLXEOLexeo TherapeuticsN/A14.1614.16TNXPTonix PharmaceuticalsN/A6.996.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLXEOLexeo Therapeutics60.67%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipLXEOLexeo Therapeutics5.30%TNXPTonix Pharmaceuticals2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLXEOLexeo Therapeutics5878.52 million74.36 millionNot OptionableTNXPTonix Pharmaceuticals5015.94 million15.62 millionNot OptionableTNXP and LXEO HeadlinesRecent News About These CompaniesTNXP: Secures commercial payer coverage for Tonmya® to provide access for ~35 million US patientsMay 22 at 8:12 AM | msn.comTNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. PatientsMay 20, 2026 | finance.yahoo.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above Two Hundred Day Moving Average - What's Next?May 19, 2026 | americanbankingnews.comTonix Pharma advances TNX-4800 Lyme vaccine programMay 15, 2026 | tipranks.comTonix Pharmaceuticals Holding (TNXP) price target decreased by 14.88% to 47.18May 14, 2026 | msn.comTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026May 14, 2026 | finance.yahoo.comTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026May 14, 2026 | globenewswire.comTonix Pharmaceuticals to Participate in Two Investor Conferences in MayMay 12, 2026 | finance.yahoo.comTonix Pharmaceuticals to Participate in Two Investor Conferences in MayMay 12, 2026 | markets.businessinsider.comTonix Pharmaceuticals to Participate in Two Investor Conferences in MayMay 12, 2026 | globenewswire.comTonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational HighlightsMay 11, 2026 | finance.yahoo.comTonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational HighlightsMay 11, 2026 | globenewswire.comTonix Pharma Shareholders Approve Reverse Split and Incentive PlanMay 7, 2026 | tipranks.comTNXP stock climbs 7%: Retail bets on $30M revenue upside from Tonmya dealMay 7, 2026 | msn.comWhy Tonix Pharmaceuticals shares are rallying WednesdayMay 7, 2026 | msn.comTonix rises on commercial payer coverage for pain therapyMay 6, 2026 | seekingalpha.comTonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. PatientsMay 6, 2026 | finance.yahoo.comTonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. PatientsMay 6, 2026 | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Upgraded by TD CowenMay 6, 2026 | marketbeat.comTD Cowen initiates coverage of Tonix Pharmaceuticals Holding (TNXP) with buy recommendationMay 6, 2026 | msn.comTonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNXP and LXEO Company DescriptionsLexeo Therapeutics NASDAQ:LXEO$5.11 -0.12 (-2.29%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$5.24 +0.13 (+2.52%) As of 05/22/2026 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Tonix Pharmaceuticals NASDAQ:TNXP$12.77 -1.23 (-8.79%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.89 +0.12 (+0.95%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
